Do you really want to set a precedent that (intellectual) property rights are suspended in times of crisis? Maybe, but I'd argue that the problem was granting

Do you really want to set a precedent that (intellectual) property rights are suspended in times of crisis? Maybe, but I'd argue that the problem was granting IP rights too strong in the first place. Patents are, in principle, a useful incentive for R&D, but when the products of that R&D are medical in nature, the ethics of allowing them to be withheld become very shaky. In particular, granting patents that allow R&D organisations to recover the true overall cost of their work and make a sufficient profit to justify the endeavour is one thing, but granting patents that allow monopoly providers to set arbitrarily high costs on essential treatments is another thing entirely. And before anyone suggests that there is no alternative to keep that research going, consider that typically it is not actually the researchers who are raking in those big profits. It is entirely possible that a centrally funded public research service that hired the same experts and provided the same labs and then used its own or external manufacturing facilities for mass production would work out more cost effective for a centralised healthcare system than the current way things work particularly in the US.